The encyclopedia · Product & Design · Product decision · 2013
Kanebo's whitening ingredient gave 19,600 users skin blotches it could not reverse
A proprietary brightening compound caused leukoderma in nearly 20,000 customers. Kanebo recalled 54 products across Asia and paid out for years.
Kanebo Cosmetics · Kao Corporation · 2013-07
What happened
In July 2013, Kanebo Cosmetics, a subsidiary of Kao Corporation, voluntarily recalled 54 skin-whitening products across Asia after consumers reported persistent white blotches — leukoderma — that did not fade after they stopped using the products. The cause was rhododenol (4HPB), a proprietary brightening ingredient Kanebo had developed and used across eight sub-brands.
Kanebo had shipped 4.36 million of the affected products in Japan alone and distributed 370,000 overseas. By early 2014, the company had confirmed 19,603 cases of vitiligo-like symptoms and reached 16,856 settlement agreements with affected consumers. Kao booked ¥11.3 billion in recall-related costs and losses, and Kanebo's operating profit fell by an estimated ¥6 billion.
The recall spanned Japan, Hong Kong, South Korea, Taiwan, Thailand, Singapore, Malaysia, Indonesia, Myanmar, the Philippines and Vietnam. In Taiwan, Kanebo's largest overseas market for the products, the local agent pulled 12 items from department-store shelves. The case became a landmark in cosmetics safety regulation across Asia.
Why it happened
- Kanebo rushed a novel active ingredient to market without adequate long-term dermatological testing across diverse skin types.
- The company treated early consumer complaints as isolated skin conditions rather than a systemic ingredient problem, delaying the recall by months.
- A single proprietary compound was embedded across 54 products and eight sub-brands, so one ingredient failure became a portfolio-wide recall.
- Kao's 2006 acquisition of Kanebo had not fully integrated safety-review processes, leaving the subsidiary's product-development pipeline under-supervised.
The lesson
A novel active ingredient needs long-term safety data before it ships in millions of units. One compound embedded across a product line turns a single failure into a portfolio-wide recall.
Aftermath
Kanebo established a compensation programme that was still paying claims years later. Kao consolidated Kanebo's operations and tightened safety review. The case prompted stricter cosmetics-ingredient regulation in Japan and across Asian markets.
Sources
- Taipei Times — Kanebo recalls 54 whitening products (2013)
- WWD — Kao 9-Month Net Profit Slips on Kanebo Recall
- The Straits Times — Japan firm Kanebo widens recall after skin-stain complaints
spotted an error? The club wants to know.
More like this
POLA Orbis launched two prestige beauty brands in 2018 — wound them up in four years
Masks killed the lipstick, so L'Oréal Paris ended 52 years of makeup in Japan in 2021
Daiichi Sankyo's ADC bet: capacity locked in before the patients existed
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.